Cargando…

The Secondary Myelodysplastic Neoplasms (MDS) Jigsaw

SIMPLE SUMMARY: The classification of myelodysplastic neoplasms (MDSs) in patients with a previous primary tumor is controversial, as an efficient consensus risk factor-based classification of secondary MDSs has not yet been established. The current classifications consider separate etiologies based...

Descripción completa

Detalles Bibliográficos
Autores principales:	Calvete, Oriol, Mestre, Julia, Jerez, Andrés, Solé, Francesc
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10000488/ https://www.ncbi.nlm.nih.gov/pubmed/36900275 http://dx.doi.org/10.3390/cancers15051483

Ejemplares similares

Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS)
por: Lucero, Josephine, et al.
Publicado: (2023)

Changed concepts and definitions of myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS) and myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in the updated 2008 WHO classification
por: Hebeda, Konnie M., et al.
Publicado: (2009)

Molecular Drivers of Myelodysplastic Neoplasms (MDS)—Classification and Prognostic Relevance
por: Hoff, Fieke W., et al.
Publicado: (2023)

Genetic Aspects of Myelodysplastic/Myeloproliferative Neoplasms
por: Palomo, Laura, et al.
Publicado: (2021)

Proliferative activity is disturbed in myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), and MDS/MPN diseases. Differences between MDS and MDS/MPN
por: Mestrum, Stefan G. C., et al.
Publicado: (2020)

Standards and Impact of Hematopathology in Myelodysplastic Syndromes (MDS)
por: Valent, Peter, et al.
Publicado: (2010)

The role of azacitidine in the management of myelodysplastic syndromes (MDS)
por: Götze, KS, et al.
Publicado: (2009)

A case of myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) successfully treated with lenalidomide
por: Islam, Anwarul
Publicado: (2015)

Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions
por: Valent, Peter, et al.
Publicado: (2017)

Myelodysplastic/Myeloproliferative Neoplasms, Unclassifiable (MDS/MPN, U): Natural history and clinical outcome by treatment strategy
por: DiNardo, CD, et al.
Publicado: (2014)

Assessing the Prognosis of Patients with Myelodysplastic Syndromes (MDS)
por: Kasprzak, Annika, et al.
Publicado: (2022)

Recurrent bilateral adrenal infarction with myelodysplastic/myeloproliferative neoplasm-unclassifiable (MDS/MPN-U): a case report
por: Hoshino, Yoshitomo, et al.
Publicado: (2023)

S170: MYELODYSPLASTIC NEOPLASMS (MDS) CLASSIFICATION FROM WHO 2017 TO WHO 2022 AND ICC 2022): AN EXPANDED ANALYSIS OF 7017 PATIENTS ON BEHALF OF THE INTERNATIONAL CONSORTIUM FOR MDS (ICMDS)
por: Komrokji, Rami S., et al.
Publicado: (2023)

Curcumin as an Epigenetic Therapeutic Agent in Myelodysplastic Syndromes (MDS)
por: Xie, Xiaoqing, et al.
Publicado: (2021)

Dysregulation of developmental and cell type-specific expression of glycoconjugates on hematopoietic cells: a new characteristic of myelodysplastic neoplasms (MDS)
por: van Spronsen, Margot F., et al.
Publicado: (2023)

Myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN with RS-T) complicated by hyperleukocytosis and gene analysis in relation to leukocytosis
por: Aoyama, Yumi, et al.
Publicado: (2019)

Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients
por: Mangaonkar, Abhishek A., et al.
Publicado: (2022)

A Single-Run Next-Generation Sequencing (NGS) Assay for the Simultaneous Detection of Both Gene Mutations and Large Chromosomal Abnormalities in Patients with Myelodysplastic Syndromes (MDS) and Related Myeloid Neoplasms
por: Liquori, Alessandro, et al.
Publicado: (2021)

Machine Learning Improves Risk Stratification in Myelodysplastic Neoplasms: An Analysis of the Spanish Group of Myelodysplastic Syndromes
por: Mosquera Orgueira, Adrian, et al.
Publicado: (2023)

The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype?
por: Snow, Anson, et al.
Publicado: (2022)

EHA Endorsement of the European Guidelines for Myelodysplastic Syndromes, MDS-RIGHT
por: Blum, Sabine, et al.
Publicado: (2021)

Iron overload in myelodysplastic syndromes (MDS) – diagnosis, management, and response criteria: a proposal of the Austrian MDS platform
por: Valent, P, et al.
Publicado: (2008)

The international jigsaw puzzle
Publicado: (2001)

The international jigsaw puzzle
por: CERN. Geneva
Publicado: (2001)

Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2021)

A new piece in the kinetochore jigsaw puzzle
por: Corbett, Kevin D., et al.
Publicado: (2014)

The Role of Non-Coding RNAs in Myelodysplastic Neoplasms
por: Georgoulis, Vasileios, et al.
Publicado: (2023)

Piecing together the FTO jigsaw
por: Frayling, Timothy M, et al.
Publicado: (2011)

“Jigsaw Puzzle” Advancement Flap
por: Sanches, Maria M., et al.
Publicado: (2018)

Journalism – De-constructing the jigsaw
por: Patel, Maya
Publicado: (2021)

Maitake mushroom extract in myelodysplastic syndromes (MDS): a phase II study
por: Wesa, Kathleen M., et al.
Publicado: (2014)

The Frank–Starling Law: a jigsaw of titin proportions
por: Sequeira, Vasco, et al.
Publicado: (2017)

Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective
por: de Witte, Theo, et al.
Publicado: (2020)

The challenge of individualised risk assessment and therapy planning in elderly high-risk myelodysplastic syndromes (MDS) patients
por: Stauder, Reinhard
Publicado: (2012)

Cytogenetic and Genetic Abnormalities with Diagnostic Value in Myelodysplastic Syndromes (MDS): Focus on the Pre-Messenger RNA Splicing Process
por: Douet-Guilbert, Nathalie, et al.
Publicado: (2022)

Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms
por: Hochman, Michael J., et al.
Publicado: (2021)

Myelodysplastic Syndromes with Isolated del(5q): Value of Molecular Alterations for Diagnostic and Prognostic Assessment
por: Acha, Pamela, et al.
Publicado: (2022)

Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS)
por: Yao, Chi-Yuan, et al.
Publicado: (2016)

Myelodysplastic Syndromes (MDS) & COVID-19: Clinical Experience from the US Epicenter of the Pandemic
por: Feld, Jonathan, et al.
Publicado: (2020)

Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T
por: Madan, Ravi A, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_l0l1o6b9dfre1okv1h0cit6uld